Assignee
VISTERRA INC
US·37 granted patents·36 pending applications·106 citations·filing 2013–2025
Top patents by PatentIndex Score
73 records- 0197US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0297US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0397US9212217B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Dec 15, 2015·14 cites·21 claims
- 0496US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0596US9365639B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Jun 14, 2016·9 cites·30 claims
- 0693US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 0793US8877200B2HA binding agentsVISTERRA INC·Filed 2013·Granted Nov 4, 2014·17 cites·9 claims
- 0892US10800835B2HA binding agentsVISTERRA INC·Filed 2018·Granted Oct 13, 2020·4 cites·20 claims
- 0992US10155806B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2016·Granted Dec 18, 2018·4 cites·30 claims
- 1092US9096657B2HA binding agentsVISTERRA INC·Filed 2014·Granted Aug 4, 2015·13 cites·30 claims
- 1191US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 1289US11912781B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2022·Granted Feb 27, 2024·1 cites·10 claims
- 1389US11230593B2Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2020·Granted Jan 25, 2022·4 cites·20 claims
- 1489US2024425569A1Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1588US11059883B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2018·Granted Jul 13, 2021·2 cites·30 claims
- 1688US10513553B2Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2016·Granted Dec 24, 2019·6 cites·22 claims
- 1787US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 1887US9969794B2HA binding agentsVISTERRA INC·Filed 2013·Granted May 15, 2018·7 cites·50 claims
- 1986US12297249B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Granted May 13, 2025·0 cites·13 claims
- 2086US12264203B2Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Apr 1, 2025·0 cites·13 claims
- 2184US12227587B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Feb 18, 2025·0 cites·10 claims
- 2283US12415865B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Sep 16, 2025·0 cites·2 claims
- 2383US12187807B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Jan 7, 2025·0 cites·4 claims
- 2483US11168131B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2016·Granted Nov 9, 2021·4 cites·15 claims
- 2581US2025059249A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2680US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 2778US12054539B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2021·Granted Aug 6, 2024·0 cites·20 claims
- 2876US11945868B2Antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2018·Granted Apr 2, 2024·1 cites·37 claims
- 2976US2025296982A1Engineered polypeptides and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3074US12024552B2Ha binding agentsVISTERRA INC·Filed 2020·Granted Jul 2, 2024·0 cites·19 claims
- 3174US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3274US2024141334A1Binding polypeptides and methods of making the sameVISTERRA INC·Filed 2023·Application pending·0 cites
- 3373US2024301065A1Antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3471US12084484B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2020·Granted Sep 10, 2024·0 cites·23 claims
- 3571US11773179B2Antibody molecules to C5aR1 and uses thereofVISTERRA INC·Filed 2021·Granted Oct 3, 2023·0 cites·4 claims
- 3671US2023365694A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2022·Application pending·0 cites
- 3771US2025171555A1Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3871US2024342300A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3970US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 4070US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 4170US2024376173A1Methods of using interleukin-2 agentsVISTERRA INC·Filed 2024·Application pending·0 cites
- 4269US2024383958A1Apelin receptor agonists and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 4368US2024366758A1Formulations of antibody molecules to dengue virusVISTERRA INC·Filed 2024·Application pending·0 cites
- 4467US2025382379A1Humanized antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 4566US12098178B2Methods of using interleukin-2 agentsVISTERRA INC·Filed 2021·Granted Sep 24, 2024·0 cites·31 claims
- 4666US2023416372A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2023·Application pending·0 cites
- 4764US12338291B2Humanized antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2020·Granted Jun 24, 2025·0 cites·21 claims
- 4864US2022267418A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2021·Application pending·0 cites
- 4963US2017145086A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2016·Application pending·0 cites
- 5062US12202885B2Formulations of antibody molecules to influenza virusVISTERRA INC·Filed 2020·Granted Jan 21, 2025·0 cites·6 claims
Showing the top 50 of 73 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →